These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24492276)

  • 21. Vascular endothelial growth factors and liver diseases.
    Shi B; Wang X; Yang Z
    Hepatogastroenterology; 2001; 48(40):1145-8. PubMed ID: 11490820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Epidemiology and natural history of cirrhosis].
    Naveau S; Perlemuter G; Balian A
    Rev Prat; 2005 Sep; 55(14):1527-32. PubMed ID: 16255293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular deterioration in cirrhosis: the big picture.
    Bosch J
    J Clin Gastroenterol; 2007; 41 Suppl 3():S247-53. PubMed ID: 17975472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pathophysiology of portal hypertension.
    Treiber G; Csepregi A; Malfertheiner P
    Dig Dis; 2005; 23(1):6-10. PubMed ID: 15920320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Circulatory dysfunction syndrome associated with liver cirrhosis].
    Hartleb M
    Przegl Epidemiol; 2005; 59(2):549-58. PubMed ID: 16190566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Morphofunctional rearrangement of the hepatic vasculature in the pathogenesis of portal hypertension in liver cirrhosis].
    Garbuzenko DV
    Ter Arkh; 2014; 86(2):90-5. PubMed ID: 24772515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Could antioxidants be the "magic pill" for cirrhosis-related complications? A pathophysiological appraisal.
    Assimakopoulos SF; Gogos C; Labropoulou-Karatza C
    Med Hypotheses; 2011 Sep; 77(3):419-23. PubMed ID: 21703771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severity of portal hypertension and prediction of postoperative liver failure after liver resection in patients with Child-Pugh grade A cirrhosis.
    Chen X; Zhai J; Cai X; Zhang Y; Wei L; Shi L; Wu D; Shen F; Lau WY; Wu M
    Br J Surg; 2012 Dec; 99(12):1701-10. PubMed ID: 23132418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hepatic blood flow, portal hypertension and liver failure in patients with alcoholic cirrhosis (author's transl)].
    Lebrec D; Sicot C; Benhamou JP
    Arch Fr Mal App Dig; 1973 Sep; 62(6):465-71. PubMed ID: 4779228
    [No Abstract]   [Full Text] [Related]  

  • 30. Pathophysiology of liver circulation with an overview of medical and invasive treatments.
    Bombardieri G; Conti LR
    Rays; 1997; 22(2):196-210. PubMed ID: 9351328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
    La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
    Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular mechanisms of increased intrahepatic resistance in portal hypertension.
    Shah V
    J Clin Gastroenterol; 2007; 41 Suppl 3():S259-61. PubMed ID: 17975474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis.
    Boleslawski E; Petrovai G; Truant S; Dharancy S; Duhamel A; Salleron J; Deltenre P; Lebuffe G; Mathurin P; Pruvot FR
    Br J Surg; 2012 Jun; 99(6):855-63. PubMed ID: 22508371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease.
    Rosmorduc O; Housset C
    Semin Liver Dis; 2010 Aug; 30(3):258-70. PubMed ID: 20665378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The afferent circulation of the liver in patients with primary hepatocellular carcinoma.
    Jakab F; Ráth Z; Schmal F; Nagy P; Faller J
    Hepatogastroenterology; 1995; 42(4):399-402. PubMed ID: 8586376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis.
    Pinzani M; Gentilini P
    Semin Liver Dis; 1999; 19(4):397-410. PubMed ID: 10643625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Splanchnic and systemic vasodilatation: the patient.
    Tsai MH
    J Clin Gastroenterol; 2007; 41 Suppl 3():S266-71. PubMed ID: 17975476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pulmonary vascular complications in portal hypertension and liver disease: a concise review.
    Porres-Aguilar M; Gallegos-Orozco JF; Garcia H; Aguirre J; Macias-Rodriguez RU; Torre-Delgadillo A
    Rev Gastroenterol Mex; 2013; 78(1):35-44. PubMed ID: 23369639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathophysiology of portal hypertension.
    Cichoz-Lach H; Celiński K; Słomka M; Kasztelan-Szczerbińska B
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():231-8. PubMed ID: 18812641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Green tea polyphenol decreases the severity of portosystemic collaterals and mesenteric angiogenesis in rats with liver cirrhosis.
    Hsu SJ; Wang SS; Hsin IF; Lee FY; Huang HC; Huo TI; Lee WS; Lin HC; Lee SD
    Clin Sci (Lond); 2014 May; 126(9):633-44. PubMed ID: 24063570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.